Inmolecule Nanotech (FRA:DC0) Debt-to-Equity: 0.00 (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:DC0 Inmolecule Nanotech SA FRA:DC0
5 GF Score
Price €3.84
! 2 Warning Signs
View Full Analysis

What is Inmolecule Nanotech Debt-to-Equity?

Inmolecule Nanotech FRA:DC0 5 Debt-to-Equity is 0.00 as of Dec. 2024. GuruFocus rates FRA:DC0 with a GF Score™ of 5/100. The stock has 2 warning signs investors should review. Among 966 Biotechnology companies, Inmolecule Nanotech ranks worse than 61.59% on this metric.

Inmolecule Nanotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.00 Mil. Inmolecule Nanotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.00 Mil. Inmolecule Nanotech's Total Stockholders Equity for the quarter that ended in Dec. 2024 was €7.39 Mil. Inmolecule Nanotech's debt to equity for the quarter that ended in Dec. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Inmolecule Nanotech's Debt-to-Equity or its related term are showing as below:

FRA:DC0' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.26   Med: 0.29   Max: 0.31
Current: 0.26

During the past 2 years, the highest Debt-to-Equity Ratio of Inmolecule Nanotech was 0.31. The lowest was 0.26. And the median was 0.29.

FRA:DC0's Debt-to-Equity is ranked worse than
61.59% of 966 companies
in the Biotechnology industry
Industry Median: 0.15 vs FRA:DC0: 0.26

Inmolecule Nanotech  (FRA:DC0) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Inmolecule Nanotech Debt-to-Equity Related Terms

Inmolecule Nanotech Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Inmolecule Nanotech's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inmolecule Nanotech Debt-to-Equity Chart

Inmolecule Nanotech Annual Data
Trend Dec23 Dec24
Debt-to-Equity
0.01 0.00

Inmolecule Nanotech Quarterly Data
Dec23 Dec24
Debt-to-Equity 0.01 0.00

FRA:DC0 vs VRTX, REGN, MRNA: Debt-to-Equity Comparison

For the Biotechnology subindustry, Inmolecule Nanotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inmolecule Nanotech Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inmolecule Nanotech's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Inmolecule Nanotech's Debt-to-Equity falls into.


FRA:DC0
5GF Score
Inmolecule Nanotech SA FRA:DC0
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inmolecule Nanotech Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Inmolecule Nanotech's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.00463938 + 0) / 7.39309271
=0.00

Inmolecule Nanotech's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.00463938 + 0) / 7.39309271
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.00 mean?
Inmolecule Nanotech (FRA:DC0) has a Debt-to-Equity of 0.00 as of Dec. 2024. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Inmolecule Nanotech and its competitors. Over the past decade, Inmolecule Nanotech's Debt-to-Equity has ranged from 0.26 to 0.31. According to the industry distribution chart, Inmolecule Nanotech ranks #595 out of 966 companies in the Biotechnology industry, placing it in the top 61.6%.
Is Inmolecule Nanotech's Debt-to-Equity too high?
Inmolecule Nanotech's current Debt-to-Equity is 0.00. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 0.31. Based on the distribution chart, Inmolecule Nanotech ranks #595 out of 966 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Inmolecule Nanotech has a GF Score™ of 5/100, reflecting its overall financial health beyond just this single metric.
How does Inmolecule Nanotech's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Inmolecule Nanotech ranks #595 out of 966 companies for Debt-to-Equity. This places Inmolecule Nanotech in the lower half of its industry. The industry median Debt-to-Equity is 0.15. Historically, Inmolecule Nanotech's own Debt-to-Equity has ranged from 0.26 to 0.31 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Inmolecule Nanotech and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inmolecule Nanotech's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inmolecule Nanotech stock overvalued right now?
Inmolecule Nanotech (FRA:DC0) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Inmolecule Nanotech's overall GF Score™ is 5/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Inmolecule Nanotech (FRA:DC0), the current Debt-to-Equity is 0.00 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Inmolecule Nanotech Business Description

Other Exchanges MLINA:France
Address Paseo de la Castellana 91, 4th Floor, Madrid, ESP, 28046
Inmolecule Nanotech SA is a research and development company. The company provides health care, home care and personal care products.
5GF Score

Get the complete analysis for FRA:DC0

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.84
Price